O
Oculis
Development of non-invasive topical treatment for back-of-the-eye diseases
About Oculis
Oculis is a clinical-stage biopharmaceutical company focused on developing novel topical treatments for ophthalmic diseases affecting both the front and back of the eye. The company primarily serves patients suffering from conditions such as diabetic macular edema (DME) and post-cataract inflammation. Operating in the biopharmaceutical market, Oculis leverages its proprietary SNP technology to create eye drop formulations that offer a non-invasive alternative to current treatments, which often involve intraocular injections or implants.
Read full description
Oculis's business model revolves around advancing its lead candidates, OCS-01 and OCS-02, through clinical trials and eventually bringing them to market. OCS-01 has shown promise in Phase 2 studies for DME and post-cataract inflammation, potentially offering a paradigm shift in how these conditions are treated. The company aims to generate revenue through the commercialization of these innovative treatments, targeting a global market of patients and healthcare providers seeking more effective and less invasive ophthalmic solutions.
At a glance
- Founded
- 2003
- Headquarters
- Switzerland
- Listing
- Public via SPAC 2023
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Icelandic Centre for Research
Series A7 investors entered at this stage
Brunnur Ventures
Silfurberg
Pivotal Life Sciences- BCBay City Capital
Novartis Venture Fund- TMTekla Capital Management
Nan Fung Life Sciences Real Estate
Series B and later12 investors entered at this stage
BVCF
Hyfinity Investments- WAWille AG
Earlybird Venture Capital
VI Partners- ECEuropean Biotech Acquisition Corp
BlackRock
Pareto Securities
H.C. Wainwright
Leerink Partners
JP Morgan
Van Lanschot Kempen
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
12 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Oculis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oculis on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.